Aviragen Therapeutics
About Aviragen Therapeutics
Aviragen Therapeutics was acquired by Vaxart in 2017 and was focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11.
Find Aviragen Therapeutics Execs' Valid Emails
Up to 90% verified emails and mobile numbers, refreshed weekly.
Company Details
10M-25M
Research Services
51-200 employees
Public Company
Alpharetta, GA
United States
Frequently Asked Questions about
What is Aviragen Therapeutics's industry?
Aviragen Therapeutics operates in the Research Services industry and is headquartered in United States.
How many employees does Aviragen Therapeutics have?
Aviragen Therapeutics has approximately 51-200 employees employees.
Where is Aviragen Therapeutics's based?
Aviragen Therapeutics is based in Alpharetta, GA, United States.
Is Aviragen Therapeutics publicly listed?
Yes. Aviragen Therapeutics is a publicly traded company.
How can I contact Aviragen Therapeutics's investor relations team?
You can reach Aviragen Therapeutics’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.